Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Breast- and Prostate Cancer

Published by: BioSeeker Group AB

Published: Jun. 11, 2007 - 380 Pages

Table of Contents

1 Executive Summary

2 Methodologies

3 Table of Contents

3.1 List of Figures

3.2 List of Tables

3.3 List of Boxes

4 Antibody Drug Target Analysis in Oncology: What and Where Are We Targeting?

5 Antibody Drug Targets by Molecular Function

5.1 Carboxypeptidase Activity Targets

5.2 Catalytic Activity Targets

5.3 Cell Adhesion Molecule Activity Targets

5.4 Chaperone Activity Targets

5.5 Chemokine Activity Targets

5.6 Cofactor Binding Targets

5.7 Complement Activity Targets

5.8 Cytokine Activity Targets

5.9 DNA Topoisomerase Activity Targets

5.10 Extracellular Matrix Structural Constituent Targets

5.11 G-protein Coupled Receptor Activity Targets

5.12 Growth Factor Activity Targets

5.13 Hormone Activity Targets

5.14 Hydrolase Activity Targets

5.15 Intracellular Ligand-gated Ion Channel Activity Targets

5.16 Metallopeptidase Activity Targets

5.17 MHC Class I Receptor Activity Targets

5.18 Molecular Function Unknown Targets

5.19 Oxidoreductase Activity Targets

5.20 Peptide Hormone Targets

5.21 Protease Inhibitor Activity Targets

5.22 Protein Binding Targets

5.23 Receptor Activity Targets

5.24 Receptor Binding Targets

5.25 Receptor Signaling Complex Scaffold Activity Targets

5.26 Receptor Signaling Protein Tyrosine Phosphatase Activity Targets

5.27 RNA-directed DNA polymerase Activity Targets

5.28 Serine-type Peptidase Activity Targets

5.29 T Cell Receptor Activity Targets

5.30 Translation Regulator Activity Targets

5.31 Transmembrane Receptor Activity Targets

5.32 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets

5.33 Transporter Activity Targets

5.34 Unclassified Targets

6 Antibody Drugs Targeting Signaling Pathways

6.1 Alpha6 Beta4 Integrin Signaling Pathway

6.1.1 Description of Pathway

6.1.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type

6.2 Androgen Receptor Signaling Pathway

6.2.1 Description of Pathway

6.2.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type

6.3 B Cell Receptor Signaling Pathway

6.3.1 Description of Pathway

6.3.2 Antibody Drugs by Target, Developmental Stage and Cancer Type

6.4 EGFR1 Signaling Pathway

6.4.1 Description of Pathway

6.4.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type

6.5 IL-2 Signaling Pathway

6.5.1 Description of Pathway

6.5.2 Antibody Drugs by Target, Developmental Stage and Cancer Type

6.6 IL-4 Signaling Pathway

6.6.1 Description of Pathway

6.6.2 Antibody Drugs by Target, Developmental Stage and Cancer Type

6.7 IL-6 Signaling Pathway

6.7.1 Description of Pathway

6.7.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type

6.8 Kit Receptor Signaling Pathway

6.8.1 Description of Pathway

6.8.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type

6.9 Notch Signaling Pathway

6.9.1 Description of Pathway

6.9.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type

6.10 T Cell Receptor Signaling Pathway

6.10.1 Description of Pathway

6.10.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type

6.11 TGF-beta Receptor Signaling Pathway

6.11.1 Description of Pathway

6.11.2 Antibody Drugs byTarget, Developmental Stage, and Cancer Type

6.12 TNF-alpha Signaling Pathway

6.12.1 Description of Pathway

6.12.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type

6.13 Wnt Signaling Pathway

6.13.1 Description of Pathway

6.13.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type

7 Antibodies Targeting Cancer Stem Cells

8 Targets of Antibody Conjugates

9 Antibody Drug Targets by Three Major Non Immunological Therapeutic Effects

9.1 Anti-Angiogenesis

9.2 Apoptosis

9.3 Protein Kinase Inhibitors

10 Antibody Targets and Drugs by Cancer Indications

10.1 Basal Cell Cancer

10.2 Biliary Cancer

10.3 Bladder Cancer

10.4 Bone Cancer

10.5 Brain Cancer

10.6 Breast Cancer

10.7 Cervical Cancer

10.8 Cervical Dysplasia

10.9 Colorectal Cancer

10.10 Endometrial Cancer

10.11 Esophageal Cancer

10.12 Fallopian Tube Cancer

10.13 Gastrointestinal Cancers

10.14 Head and Neck Cancer

10.15 Leukemias

10.16 Liver Cancer

10.17 Lung Cancers

10.18 Lymphomas

10.19 Melanoma

10.20 Mesothelioma

10.21 Myelodysplastic syndrome

10.22 Myelomas

10.23 Nasopharyngeal Cancer

10.24 Oesophageal Cancer

10.25 Ovarian Cancer

10.26 Pancreatic Cancer

10.27 Peritoneal Cancer

10.28 Prostate Cancer

10.29 Renal Cancers

10.30 Sarcomas

10.31 Thyroid Cancer

11 Expression Profiles of Antibody Drug Targets

11.1 Human Tissues and Cancer Tissues

11.2 Cancer Lines and Cells

12 Breast Cancer: An Introduction

12.1 Disease Definitions

12.2 Etiology

12.3 Epidemiology

12.4 Prognosis

13 Current Treatment Strategies of Breast cancer

13.1 Localized Disease

13.2 Advanced Disease

14 Progress in Current Breast Cancer Treatment Strategies

14.1 Hormone Based Therapies

14.2 Antibodies

14.3 Chemotherapy

14.4 Chemotherapy

15 Key Therapeutic Strategies for Future Breast Cancer Therapies

15.1 Therapeutic Type, Targets & Mechanisms

16 Competitive Landscape in Breast Cancer Drug Development: The Late Stage Pipeline

16.1 The Epothilones

16.2 Cell Cycle & Apoptosis

16.3 Protein Kinase Inhibitors

16.4 Immunotherapy

17 Current Drug Development for Breast Cancer: The Early Stage Pipeline

17.1 DNA Targeting

17.2 FTIs

17.3 Antisense

17.4 New Hormone Modulators

17.5 Other

18 Prostate Cancer: An Introduction

18.1 Disease Definitions

18.2 Etiology & Pathophysiology

18.3 Epidemiology

18.4 Prognosis

19 Current Prostate Cancer Treatment Strategies

19.1 Localized Disease

19.1.1 Locally Advanced Prostate Cancer

19.2 Metastatic Prostate Cancer

19.2.1 Hormone-Sensitive Metastatic Prostate Cancer

19.2.2 Hormone-Refractory or Recurrent Metastatic Prostate Cancer

20 Progress in Current Prostate CancerTreatment Strategies

20.1 Long-Term Follow-up Data not yet Been Published

20.2 Significant Reduced Risk of Distant Metastases

20.3 Adverse Events

20.4 No Difference in Overall Survival

20.5 Cross-over Design an Optimal Option?

20.6 Death due to Liver Failure

20.7 Survival Benefit

20.8 Subdermal Implant

20.9 No FDA Approval

20.10 No Improvement in 5-year Disease-Free Survival

20.11 Effective Secondary Hormonal Therapy?

20.12 Synery in Combination

21 Key Therapeutic Strategies for Future Prostate Cancer Therapies

21.1 Therapeutic Type, Targets & Mechanisms

22 Competitive Landscape in Prostate Cancer Drug Development: The Late Stage Pipeline

22.1 Reduced Prostate Cancer Risk

22.2 High Activity in Metastatic AIPC Patients

22.3 Absence of Severe Toxicities

22.4 Waiting for Data

22.5 Probability of Regulatory Approval?

22.6 Co-development and License Agreement

22.7 Improves Predicted Survival?

22.8 Slow Progress & Development Partners

22.9 Exclusive License Agreement

23 Current Prostate Cancer Drug Development: The Early Stage Pipeline

23.1 New Data?

23.2 Terminated Study

23.3 More Than 50% PSA decline

23.4 Safety and Tolerability

23.5 Terminated?

23.6 Marker of Drug Effect

23.7 Preliminary Results for a Tyrosine Kinase Inhibitor

23.8 No Activity in Monotherapy

23.9 Dramatic Disappearance of Bone Metastatic Lesions

23.10 PSA Response - Anthracycline

24 Disclaimer

25 Drug Index

26 Company Index

27 Appendix I: Antibody Targets by Companies

3.1 List of Figures

Figure 1: Antibody Pipeline Maturity by Molecular Function Classes of Targets 1(3)

Figure 2: Antibody Pipeline Maturity by Molecular Function Classes of Targets 2(3)

Figure 3: Antibdody Pipeline Maturity by Molecular Function Classes of Targets 3(3)

Figure 4: Pipeline Maturation of Carboxypeptidase Activity Targets

Figure 5: Number of Antibody Drugs per Cancer Indication and Carboxypeptidase Activity Target

Figure 6: Pipeline Maturation of Catalytic Activity Targets

Figure 7: Number of Antibody Drugs per Cancer Indication and Catalytic Activity Target

Figure 8: Pipeline Maturation of Cell Adhesion Molecule Activity Targets

Figure 9: Number of Antibody Drugs per Cancer Indication and Cell Adhesion Molecule Activity Target

Figure 10: Pipeline Maturation of Chaperone Activity Targets

Figure 11: Number of Antibody Drugs per Cancer Indication and Chaperone Activity Target

Figure 12: Pipeline Maturation of Chemokine Activity Targets

Figure 13: Number of Antibody Drugs per Cancer Indication and Chemokine Activity Target

Figure 14: Pipeline Maturation of Cofactor Binding Targets

Figure 15: Number of Antibody Drugs per Cancer Indication and Cofactor Binding Target

Figure 16: Pipeline Maturation of Complement Activity Targets

Figure 17: Number of Antibody Drugs per Cancer Indication and Complement Activity Target

Figure 18: Pipeline Maturation of Cytokine Activity Targets

Figure 19: Number of Antibody Drugs per Cancer Indication and Cytokine Activity Target

Figure 20: Pipeline Maturation of DNA Topoisomerase Activity Targets

Figure 21: Number of Antibody Drugs per Cancer Indication and DNA Topoisomerase Activity Target

Figure 22: Pipeline Maturation of Extracellular Matrix Structural Constituent Targets

Figure 23: Number of Antibody Drugs per Cancer Indication and Extracellular Matrix Structural Constituent Target

Figure 24: Pipeline Maturation of G-protein Coupled Receptor Activity Targets

Figure 25: Number of Antibody Drugs per Cancer Indication and Extracellular G-protein Coupled Receptor Activity Target

Figure 26: Pipeline Maturation of Growth Factor Activity Targets

Figure 27: Number of Antibody Drugs per Cancer Indication and Extracellular Growth Factor Activity Target

Figure 28: Pipeline Maturation of Hormone Activity Targets

Figure 29: Number of Antibody Drugs per Cancer Indication and Hormone Activity Target

Figure 30: Pipeline Maturation of Hydrolase Activity Targets

Figure 31: Number of Antibody Drugs per Cancer Indication and Hydrolase Activity Target

Figure 32: Pipeline Maturation of Ligand-gated Ion Channel Activity Targets

Figure 33: Number of Antibody Drugs per Cancer Indication and Intracellular Ligand-gated Ion Channel Activity Target

Figure 34: Pipeline Maturation of Metallopeptidase Activity Targets

Figure 35: Number of Antibody Drugs per Cancer Indication and Intracellular Metallopeptidase Activity Target60

Figure 36: Pipeline Maturation of MHC Class I Receptor Activity Targets

Figure 37: Number of Antibody Drugs per Cancer Indication and MHC Class I Receptor Activity Target

Figure 38: Pipeline Maturation of Molecular Function Unknown Targets

Figure 39: Number of Antibody Drugs per Cancer Indication and Molecular Function Unknown Target

Figure 40: Pipeline Maturation of Oxidoreductase Activity Targets

Figure 41: Number of Antibody Drugs per Cancer Indication and Oxidoreductase Activity Target

Figure 42: Pipeline Maturation of Peptide Hormone Targets

Figure 43: Number of Antibody Drugs per Cancer Indication and Peptide Hormone Target

Figure 44: Pipeline Maturation of Protease inhibitor Activity Targets

Figure 45: Number of Antibody Drugs per Cancer Indication and Protease Inhibitor Activity Target

Figure 46: Pipeline Maturationof Protein Binding Targets

Figure 47: Number of Antibody Drugs per Cancer Indication and Protein Binding Target

Figure 48: Pipeline Maturation of Receptor Activity Targets 1 (2)

Figure 49: Number of Antibody Drugs per Cancer Indication and Receptor Activity Target 1(2)

Figure 50: Pipeline Maturation of Receptor Activity Targets 2 (2)

Figure 51: Number of Antibody Drugs per Cancer Indication and Receptor Activity Target 2(2)

Figure 52: Pipeline Maturationof Receptor Binding Targets

Figure 53: Number of Antibody Drugs per Cancer Indication and Receptor Binding Target

Figure 54: Pipeline Maturation of Receptor Signaling Complex Scaffold Activity Targets

Figure 55: Number of Antibody Drugs per Cancer Indication and Receptor Signaling Complex Scaffold Activity Target

Figure 56: Pipeline Maturation of by Receptor Signaling Protein Tyrosine Phosphatase Activity Targets

Figure 57: Number of Antibody Drugs per Cancer Indication and Receptor Signaling Protein Tyrosine Phosphatase Activity Target

Figure 58: Pipeline Maturation of RNA-directed DNA polymerase Activity Targets

Figure 59: Number of Antibody Drugs per Cancer Indication and RNA-directed DNA polymerase Activity Target

Figure 60: Pipeline Maturation of Serine-type Peptidase Activity Targets

Figure 61: Number of Antibody Drugs per Cancer Indication and RNA Serine-type Peptidase Activity Target

Figure 62: Pipeline Maturation of T cell Receptor Activity Targets

Figure 63: Number of Antibody Drugs per Cancer Indication and T cell Receptor Activity Target

Figure 64: Pipeline Maturation of Translation Regulator Activity Targets

Figure 65: Number of Antibody Drugs per Cancer Indication and Translation Regulator Activity Target

Figure 66: Pipeline Maturation of Transmembrane Receptor Activity Targets

Figure 67: Number of Antibody Drugs per Cancer Indication and Transmembrane Receptor Activity Target

Figure 68: Pipeline Maturation of Transmembrane Receptor Protein Tyrosine Kinase Activity Targets

Figure 69: Number of Antibody Drugs per Cancer Indication and Transmembrane Receptor Protein Tyrosine

Kinase Activity Target

Figure 70: Pipeline Maturation of Transporter Activity Targets

Figure 71: Number of Antibody Drugs per Cancer Indication and Transporter Activity Target

Figure 72: Pipeline Maturation of Unclassified Targets

Figure 73: Number of Antibody Drugs per Cancer Indication and Unclassified Target

Figure 74: Antibody Pipeline Comparison of Targeted Signaling Pathways in Oncology

Figure 75: Pipeline Maturation of Immunoconjugated Antibody Targets

Figure 76: Number of Immunoconjugated Antibody Drugs per Cancer Indication and Target

3.2 List of Tables

Table 1: Molecular Functions versus Oncology Antibody Drug Targets

Table 2: Cancer Antibody Pipeline Listed by Carboxypeptidase Activity Targets

Table 3: Cancer Antibody Pipeline Listed by Catalytic Activity Targets

Table 4: Cancer Antibody Pipeline Listed by Cell Adhesion Molecule Activity Targets

Table 5: Cancer Antibody Pipeline Listed by Chaperone Activity Targets

Table 6: Cancer Antibody Pipeline Listed by Chemokine Activity Targets

Table 7: Cancer Antibody Pipeline Listed by Cofactor Binding Targets

Table 8: Cancer Antibody Pipeline Listed by Complement Activity Targets

Table 9: Cancer Antibody Pipeline Listed by Cytokine Activity Targets

Table 10: Cancer Antibody Pipeline Listed by DNA Topoisomerase Activity Targets

Table 11: Cancer Antibody Pipeline Listed by Extracellular Matrix Structural Constituent Targets

Table 12: Cancer Antibody Pipeline Listed by G-protein Coupled Receptor Activity Targets

Table 13: Cancer Antibody Pipeline Listed by Growth Factor Activity Targets

Table 14: Cancer Antibody Pipeline Listed by Hormone Activity Targets

Table 15: Cancer Antibody Pipeline Listed by Hydrolase Activity Targets

Table 16: Cancer Antibody Pipeline Listed by Intracellular Ligand-gated Ion Channel Activity Targets

Table 17: Cancer Antibody Pipeline Listed by Metallopeptidase Activity Targets

Table 18: Cancer Antibody Pipeline Listed by MHC Class I Receptor Activity Targets

Table 19: Cancer Antibody Pipeline Listed by Molecular Function Unknown Targets

Table 20: Cancer Antibody Pipeline Listed by Oxidoreductase Activity Targets

Table 21: Cancer Antibody Pipeline Listed by Peptide Hormone Targets

Table 22: Cancer Antibody Pipeline Listed by Protease inhibitor Activity Targets

Table 23: Cancer Antibody Pipeline Listed by Protein Binding Targets

Table 24: Cancer Antibody Pipeline Listed by Receptor Activity Targets

Table 25: Cancer Antibody Pipeline Listed by Receptor Binding Targets

Table 26: Cancer Antibody Pipeline Listed by Receptor Signaling Complex Scaffold Activity Targets

Table 27: Cancer Antibody Pipeline Listed by Receptor Signaling Protein Tyrosine Phosphatase Activity Targets84

Table 28: Cancer Antibody Pipeline Listed by RNA-directed DNA polymerase Activity Targets

Table 29: Cancer Antibody Pipeline Listed by Serine-type Peptidase Activity Targets

Table 30: Cancer Antibody Pipeline Listed by T cell Receptor Activity Targets

Table 31: Cancer Antibody Pipeline Listed by Translation Regulator Activity Targets

Table 32: Cancer Antibody Pipeline Listed by Transmembrane Receptor Activity Targets

Table 33: Cancer Antibody Pipeline Listed by Transmembrane Receptor Protein Tyrosine Kinase Activity Targets

Table 34: Cancer Antibody Pipeline Listed by Transporter Activity Targets

Table 35: Cancer Antibody Pipeline Listed by Unclassified Targets

Table 36: Antibody Drugs Targeting Signaling Pathways

Table 37: Signaling Pathway Analysis of Oncology Antibody Drug Targets

Table 38: Targets Linking Antibody Drugs to the Alpha6 Beta4 Integrin Signaling Pathway

Table 39: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Alpha6 Beta4 Integrin Signaling Pathway

Table 40: Targets Linking Antibody Drugs to the Androgen Receptor Signaling Pathway

Table 41: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Androgen Receptor Signaling Pathway

Table 42: Targets Linking Antibody Drugs to the B Cell Receptor Signaling Pathway

Table 43: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the B Cell Receptor Signaling Pathway

Table 44: Targets Linking Antibody Drugs to the EGFR1 Signaling Pathway

Table 45: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the EGFR1 Signaling Pathway

Table 46: Targets Linking Antibody Drugs to the IL-2 Signaling Pathway

Table 47: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the IL-2 Signaling Pathway

Table 48: Targets Linking Antibody Drugs to the IL-4 Signaling Pathway

Table 49: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the IL-4 Signaling Pathway

Table 50: Targets Linking Antibody Drugs to the IL-6 Signaling Pathway

Table 51: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the IL-6 Signaling Pathway

Table 52: Targets Linking Antibody Drugs to the Kit Receptor Signaling Pathway

Table 53: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Kit Receptor Signaling Pathway

Table 54: Targets Linking Antibody Drugs to the Notch Signaling Pathway

Table 55: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Notch Signaling Pathway

Table 56: Targets Linking Antibody Drugs to the T Cell Receptor Signaling Pathway

Table 57: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the T Cell Receptor Signaling Pathway

Table 58: Targets Linking Antibody Drugs to the TGF-beta Receptor Signaling Pathway

Table 59: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the TGF-beta Receptor Signaling Pathway

Table 60: Targets Linking Antibody Drugs to the TNF-alpha Signaling Pathway

Table 61: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the TNF-alpha Signaling Pathway

Table 62: Targets Linking Antibody Drugs to the Wnt Signaling Pathway

Table 63: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Wnt Signaling Pathway

Table 64: Cell Surface Markers of Identified Cancer Stem Cells in Human Tumors

Table 65: Signaling Pathways Involved in Stem Cell Self-Renewal

Table 66: Immunoconjugated Antibody Targets According to Molecular Function of Target

Table 67: Immunoconjugated Antibody Pipeline According to Target

Table 68: Antibodies in Oncology Reported to Affect Angiogenesis

Table 69 Antibodies in Oncology Reported to Affect Apoptosis

Table 70: Antibody Drug Protein Kinase Targets Ranked by Probability of Carrying at Least One Driver Mutation, Conditional on the Gene-Specific Selection Pressures

Table 71: Antibodies in Oncology Reported to Act as Protein Kinase Inhibitors

Table 72: Cancer Indicaions by Number of Known Antibody Targets, Number of Antibody Drugs, and Highest Developmental Stage

Table 73: Antibody Pipeline by Targets in Basal Cell Cancer

Table 74: Antibody Pipeline by Targets in Biliary Cancer

Table 75: Antibody Pipeline by Targets in Bladder Cancer

Table 76: Antibody Pipeline by Targets in Bone Cancer

Table 77: Antibody Pipeline by Targets in Brain Cancer

Table 78: Antibody Pipeline by Targets in Breast Cancer

Table 79: Antibody Pipeline by Targets in Cervical Cancer

Table 80: Antibody Pipeline by Targets in Cervical Dysplasia

Table 81: Antibody Pipeline by Targets in Colorectal Cancer

Table 82: Antibody Pipeline by Targets in Endometrial Cancer

Table 83: Antibody Pipeline by Targets in Esophageal Cancer

Table 84: Antibody Pipeline by Targets in Fallopian Tube Cancer

Table 85: Antibody Pipeline by Targets in Gastrointestinal Cancers

Table 86: Antibody Pipeline by Targets in Head and Neck Cancer

Table 87: Antibody Pipeline by Targets in Leukemias

Table 88: Antibody Pipeline by Targets in Liver Cancer

Table 89: Antibody Pipeline by Targets in Lung Cancers

Table 90: Antibody Pipeline by Targets in Lymphomas

Table 91: Antibody Pipeline by Targets in Melanoma

Table 92: Antibody Pipeline by Targets in Mesothelioma

Table 93: Antibody Pipeline by Targets in Myelodysplastic syndrome

Table 94: Antibody Pipeline by Targets in Myelomas

Table 95: Antibody Pipeline by Targets in Nasopharyngeal Cancer

Table 96: Antibody Pipeline by Targets in Oesophageal Cancer

Table 97: Antibody Pipeline by Targets in Ovarian Cancer

Table 98: Antibody Pipeline by Targets in Pancreatic Cancer

Table 99: Antibody Pipeline by Targets in Peritoneal Cancer

Table 100: Antibody Pipeline by Targets in Prostate Cancer

Table 101: Antibody Pipeline by Targets in Renal Cancers

Table 102: Antibody Pipeline by Targets in Sarcomas

Table 103: Antibody Pipeline by Targets in Thyroid Cancer

Table 104: Expression Profiles of Antibody Drug Targets in Oncology

Table 105: The Stage System

Table 106: Risk Factors

Table 107: List of Approved Drugs and Their Mechanisms of Action.

Table 108: Hormonal Treatment Strategies

Table 109: Adjuvant Systemic Treatment Options for Women With Axillary Node-Negative Breast Cancer ..... 180

Table 110: Treatment Options for Women With Axillary Node-Positive Breast Cancer

Table 111: Chemotherapy Drugs and Regimen

Table 112: Summay of Drugs Involved in Breast Cancer Therapy

Table 113: Short Facts Tamoxifen

Table 114: Short Facts Anastrozole

Table 115: Short Facts Letrozole

Table 116: Short Facts Exemestane

Table 117: Short Facts Goserelin

Table 118: Short Facts Fulvestrant

Table 119: Short Facts Trastuzumab

Table 120 Cancer Immunotherapy Strategies

Table 121: Progress on Ixabepilone

Table 122: Progress on CCI-779

Table 123: Progress on Fenretinide

Table 124: Progress on Lapatinib

Table 125: Progress on Bevacizumab

Table 126: Progress on Theratope

Table 127: Summary of Mid-Stage to Late stage Investigational Agents Under Development

Table 128: Summary of Breast Cancer Early Stage Pipeline

Table 129: The TNM System

Table 130: Lifestyle factors

Table 131: Historical Summary of Clinical Studies on Patients with Late Stage Disease

Table 132: Short Facts Abarelix

Table 133: Short Facts Bicalutamide

Table 134: Short Facts Carboplatin

Table 135: Short Facts Docetaxel

Table 136: Short Facts Mitoxantrone

Table 137: Short Facts Flutamide

Table 138: Short Facts Goserelin

Table 139: Short Facts Histrelin

Table 140: Short Facts Lanreotide

Table 141: Short Facts Leuprolide

Table 142: Short Facts Nilutamide

Table 143: Short Facts Estramustine

Table 144: Summary of Recent Clinical Studies on Patients with Late Stage Disease

Table 145: Ongoing Late Stage Clinical Studies

Table 146: Cancer Immunotherapy Strategies

Table 147: Near Term Progress Toremifene

Table 148: Near Term Progress Bevacizumab

Table 149: Near Term Progress Oblimersen

Table 150: Near Term Progress R-flurbiprofen

Table 151: Near Term Progress APC8015 platin

Table 153: Near Term Progress GVAX

Table 154: Near Term Progress Exisulind

Table 155: Summary of Prostate Cancer Late Stage Pipeline

Table 156: Paclitaxel

Table 157: Epothilone

Table 158: Ixabepilone

Table 159: PTK/ZK

Table 160: Arsenic trioxide

Table 161: Retinoic Acid

Table 162: Imatinib

Table 163: Bortezomib

Table 164: Sorafenib

Table 165: Doxorubicin

Table 166: Summary of Prostate Cancer Early Stage Pipeline

3.3 List of Boxes

Box 1: Ongoing Phase III Studies Anastrozole

Box 2: Ongoing Phase III Studies Letrozole

Box 3: Ongoing Phase III Studies Exemestane

Box 4: Ongoing Phase III Studies Goserelin

Box 5: Ongoing Phase III Studies Fulvestrant

Box 6: Ongoing Phase III Studies Trastuzumab

Box 7: The TRAIL Receptor family

Box 8: The Bcl-2 family of proteins

Box 9: Quick Facts - BMS-247550

Box 10: Quick Facts - Temsirolimus

Box 11: Quick Facts - SDX-105

Box 12: Quick Facts - 4HPR

Box 13: Quick Facts - Lapatinib

Box 14: Quick Facts - Bevacizumab

Box 15: Quick Facts - Theratope

Box 16: Erlotinib

Box 17: Gefitinib

Box 18: Imatinib

Box 19: Pemetrexed

Box 20: NX473

Box 21: Lonafarnib

Box 22: Tipifarnib

Box 23: Bortezomib

Box 24: Arzoxifene

Box 25: Patupilone

Box 26: KOS-862

Box 27: Southwest Oncology Group Study 99-16 Design

Box 28: TAX 327 Study Design

Box 29: The TRAIL Receptor family

Box 30: The Bcl-2 family of proteins

Box 31: Quick Facts - Toremifene

Box 32: Quick Facts - Bevacizumab

Box 33: Quick Facts - Genasense

Box 34: Quick Facts - R-flurbiprofen

Box 35: Quick Facts - Provenge

Box 36: Quick Facts - Satraplatin

Box 37: Quick Facts - GVAX

Box 38: Quick Facts - Exisulind

Box 39: Quick Facts - Vapreotide

Box 40: Quick Facts - DCVax

Abstract

In this triple analysis report BioSeeker Group has analyzed three major and intertwined areas of cancer R&D, Antibody drug targets, Breast- and Prostate cancer, which are all subjects to an extensive number of innovative drug candidates. This extensive 380+ pages report compiles and analyzes in parallel the progress concerning drug development and competitive situation in Antibody drug targeting and further give an in depth analysis in two key oncology areas; Breast- and Prostate cancer. The report will not only provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors.

There are currently more than 400 antibody based drugs in development for the treatment of cancer. BioSeeker has surveyed these antibodies and identified 132 antibody drug targets, belonging to 220 antibody drugs. In all they range from preclinical development to established therapy leaders in the market place. In total more than 420 clinical trials are included in this analysis, covering more than 30 different cancer indications plus diagnosis and supportive care.

Drug targets and their associated antibodies have been analyzed by BioSeeker according to:

• 34 Different molecular functions of target
• 13 Major signaling pathways
• Cancer stem cells
• Conjugated antibodies
• Therapeutic effects: Anti-angiogenesis, Apoptosis and Protein Kinase Inhibition
• 31 Targeted cancer indications
• Availability of expression profiles of targets in human tissues, cancer tissues, established cell lines and primary cell cultures
• Antibody therapeutic companies

In breast cancer we have identified 170 drug candidates in clinical stage of development and more than 100 companies are involved in the development of these drugs. As a treatment for breast cancer hormone modifying therapies together with different chemotherapeutic schedules have been of highest interest during the last years of progress. A vast amount of new clinical research data has emerged and several new clinical trials have been iniated and others generated new results. Protein kinase inhibitors and epothilones have generated substantial amount of new research data in this field. But, other strategies seem not successful and we are still waiting new information regarding their progress.

In prostate cancer we have identified 127 drug candidates in phase II or III stage of development and more than 85 companies are involved in the development of these drugs. Two of the most successful strategies are apoptosis inducers and cell based vaccines. Three out of 10 late stage candidates are apoptosis inducers. Cell based vaccines has been tried for some time but has so far failed to generate substantial improvements.

Breast and Prostate Cancer Highlights

• Thorough examination of status and impact of several novel drugs in development
• Discussion of the challenges in current and future treatment strategies
• Anticancer pipeline of most companies in the field

Key reasons to read this report

• This report serves as a serious reference for professionals interested in the development of oncology drug targets and selection/validation of targeting strategies.
• Explore the strengths and weaknesses associated with compounds in clinical development. Scientific rationale for most novel therapeutics in breast- and prostate cancer R&D, and the results of clinical trials to date
• Gain insight into the current challenges and commercial opportunities associated with breast- and prostate cancer therapy

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.